Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

Emergence of protein kinase CK2 as a key target in cancer therapy

(2010) Janeen H. Trembley et al.   BIOFACTORS

Antitumor Activity of Pyridocarbazole and Benzopyridoindole Derivatives that Inhibit Protein Kinase CK2

(2010) R. Prudent et al.   CANCER RESEARCH

CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy

(2010) A. Siddiqui-Jain et al.   CANCER RESEARCH

Structural basis of CX-4945 binding to human protein kinase CK2

(2010) Andrew D. Ferguson et al.   FEBS LETTERS

Discovery and SAR of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer

(2010) Fabrice Pierre et al.   JOURNAL OF MEDICINAL CHEMISTRY

Resorufin: a lead for a new protein kinase CK2 inhibitor

(2009) Iben Skjøth Sandholt et al.   ANTI-CANCER DRUGS

Addiction to protein kinase CK2: A common denominator of diverse cancer cells?

(2009) Maria Ruzzene et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Synthesis of new analogs of benzotriazole, benzimidazole and phthalimide—potential inhibitors of human protein kinase CK2

(2009) Andzelika Najda-Bernatowicz et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction

(2009) Ji Luo et al.   CELL

New Protein Kinase CK2 Inhibitors: Jumping out of the Catalytic Box

(2009) Renaud Prudent et al.   CHEMISTRY & BIOLOGY

How druggable is protein kinase CK2?

(2009) Giorgio Cozza et al.   MEDICINAL RESEARCH REVIEWS

Inhibition of protein kinase CK2 expression and activity blocks tumor cell growth

(2009) Dan Zhu et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

The selectivity of inhibitors of protein kinase CK2: an update

(2008) Mario A. Pagano et al.   BIOCHEMICAL JOURNAL